Currently, there are only two strategic treatments available that are clinically approved for the treatment of Alzheimer’s disease, i.e., acetylcholine esterase inhibitors, which include donepezil, tacrine, galantamine, rivastigmine, and N-methyl-D-aspartate receptor antagonist (memantine), but these are only used for symptom improvement and have poor bioavailability, non-selectivity, limited therapeutic effect, a narrow therapeutic window, hepatotoxicity, and adverse peripheral cholinergic side effects, which limit the use of these drugs. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.